Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent.~* Age ≥ 18 years and of either sex.~* Willing to comply with protocol instructions, including allowing all study assessments.~* Have a venous leg ulcer (VLU) between the knee and ankle (at or above the malleolus), with a surface area ≥ 2.0 cm2 and ≤ 12.0 cm2~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.~* Arterial supply adequacy confirmed~* Target ulcer involves a full thickness skin loss, but WITHOUT exposure of tendon, muscle, or bone.~* Target ulcer duration ≥ 6 weeks but ≤ 104 weeks (24 months).~* Acceptable state of health and nutrition~Exclusion Criteria:~* History of anaphylaxis, serum sickness, or erythema multiforme reaction to aprotinin, bovine serum albumin or bovine serum proteins, penicillin, streptomycin, amphotericin B.~* Prior diagnosis of Systemic Lupus Erythematosus with elevated anti-DNA antibody titers, Buerger's disease (thromboangiitis obliterans), current diagnosis of vasculitis, or current diagnosis of claudication.~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.~* A target ulcer of non-venous etiologies (e.g., sickle cell anemia, necrobiosis lipoidica diabeticorum, pyoderma gangrenosum, vasculopathic or vasculitic).~* Documented history of osteomyelitis at the target wound location within 6 months preceding the Screening Visit.~* Refusal of or inability to tolerate compression therapy.~* Therapy of the target ulcer with autologous skin graft, Apligraf™, or Dermagraft™ within 30 days preceding the Screening Visit.~* History of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancers).~* Any prior exposure to HP802-247 or its vehicle.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HP802-247 plus compression therapy (Type: EXPERIMENTAL): HP802-247 (fibrinogen solution \& thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days. Subjects randomized to HP802-247 will receive Vehicle on alternate weeks.
- HP802-247 Vehicle plus compression therapy (Type: PLACEBO_COMPARATOR): fibrinogen solution \& thrombin solution without cells. Subjects randomized to HP802-247 Vehicle will receive Vehicle weekly.

Based on this trial design, predict the completion outcome and termination type (if applicable).